Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurisco Pharmaceutical CoSHSE:605116 -1.88%78 Days Payable is 170.29 as of Mar. 2026, which is 60% above its 10-year median of 106.62. GuruFocus rates SHSE:605116 with a GF Score™ of 78/100 and a GF Value™ of ¥28.92 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Aurisco Pharmaceutical Co ranks better than 58.4% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:605116 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Aurisco Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurisco Pharmaceutical Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurisco Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Aurisco Pharmaceutical Co's Days Payable falls into.
Aurisco Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aurisco Pharmaceutical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurisco Pharmaceutical Co (SHSE:605116) has a Days Payable of 170.29 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurisco Pharmaceutical Co and its competitors. This is 60% above median its historical median of 106.62. Over the past decade, Aurisco Pharmaceutical Co's Days Payable has ranged from 84.41 to 191.33. According to the industry distribution chart, Aurisco Pharmaceutical Co ranks #292 out of 702 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Aurisco Pharmaceutical Co's Days Payable too high?
Aurisco Pharmaceutical Co's current Days Payable of 170.29 is 60% above median its 10-year median of 106.62. Over the past 10 years, this metric has ranged from a low of 84.41 to a high of 191.33. The Biotechnology industry median Days Payable is 113.10. Aurisco Pharmaceutical Co's value of 170.29 is 50.6% above this industry median. Based on the distribution chart, Aurisco Pharmaceutical Co ranks #292 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aurisco Pharmaceutical Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aurisco Pharmaceutical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aurisco Pharmaceutical Co ranks #292 out of 702 companies for Days Payable. This puts Aurisco Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 113.10. Aurisco Pharmaceutical Co's value of 170.29 is 50.6% above this benchmark. Historically, Aurisco Pharmaceutical Co's own Days Payable has ranged from 84.41 to 191.33 over the past decade. While the company's 10-year median is 106.62 vs. the industry median of 113.10, Aurisco Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurisco Pharmaceutical Co's current Days Payable of 170.29 is 50.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurisco Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurisco Pharmaceutical Co's current Days Payable is 170.29, which is 60% above median its own 10-year median of 106.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurisco Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co (SHSE:605116) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥28.92, compared to a current price of ¥18.74 — trading 35.2% below its estimated fair value. The current Days Payable is 170.29, which is 60% above median its 10-year median of 106.62 and 50.6% above the Biotechnology industry median of 113.10. Aurisco Pharmaceutical Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aurisco Pharmaceutical Co (SHSE:605116), the current Days Payable is 170.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurisco Pharmaceutical Co (SHSE:605116) Overvalued in 2026?
Based on GuruFocus' analysis, Aurisco Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥18.74 is trading 35.2% below its estimated GF Value™ of ¥28.92.
GuruFocus considers Aurisco Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:605116:
Days Payable: 170.29 (60% above median its 10-year median of 106.62)
GF Value™: ¥28.92 vs. price of ¥18.74 (35.2% below fair value)
Industry Position: 50.6% above the Biotechnology median (#292 of 702)
No single metric tells the full story. See the SHSE:605116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurisco Pharmaceutical Co Ltd is engaged in production and sales of specialty APIs and pharmaceutical intermediates. The company's products include API's and Intermediates. Its products are supplied to Asia, Europe, America and Middle East through a well-established sales network.
78GF Score
Get the complete analysis for SHSE:605116
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605116 has been successfully added to your 
